Related Experiment Video

Updated: Jun 12, 2025

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

769

Severe thrombocytopenia is associated with adverse pregnancy outcomes in patients with obstetric antiphospholipid

Jiayang Jin1,2, Mengyao Zhang1,2, Xuanlin Cai1,2

  • 1Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, 100044, China.

European Journal of Medical Research
|June 9, 2025
PubMed

Insights

Severe thrombocytopenia in obstetric antiphospholipid syndrome (OAPS) patients significantly increases adverse pregnancy outcomes (APOs). Maintaining platelet counts above 50 × 10^9/L is crucial for mitigating these risks in OAPS pregnancies.

Area of Science:

  • Obstetrics and Gynecology
  • Hematology
  • Rheumatology

Background:

  • Thrombocytopenia is a frequent complication in antiphospholipid syndrome (APS).
  • Obstetric APS (OAPS) specifically involves pregnancy, presenting unique challenges.
  • The link between severe thrombocytopenia and adverse pregnancy outcomes (APOs) in OAPS requires detailed investigation.

Purpose of the Study:

  • To evaluate the association between severe thrombocytopenia and adverse pregnancy outcomes (APOs) in patients with obstetric antiphospholipid syndrome (OAPS).
  • To identify a potential threshold for platelet count below which APO risk significantly increases in OAPS patients.

Main Methods:

  • An observational cohort study was conducted.
  • Demographic, clinical, immunologic, and pregnancy outcome data were collected from 176 OAPS patients.
  • Univariate and multivariate logistic regression analyses, along with piecewise linear regression, were used to assess the association between severe thrombocytopenia (platelet count < 30 × 10^9/L) and APOs.

Main Results:

  • Severe thrombocytopenia (< 30 × 10^9/L) was significantly associated with increased risks of preterm delivery before 34 weeks, uteroplacental insufficiency, preterm labor before 37 weeks, and small for gestational age (SGA).
  • A nonlinear relationship was observed, with APO risk increasing as platelet counts decreased to a threshold of 50 × 10^9/L.
  • Platelet counts above 50 × 10^9/L showed no significant association with APO risk.

Conclusions:

  • The severity of thrombocytopenia is a critical factor influencing adverse pregnancy outcomes in OAPS patients.
  • Maintaining platelet counts above 50 × 10^9/L is essential for reducing the risk of APOs in OAPS pregnancies.
  • Effective management and treatment of OAPS may lead to improved pregnancy outcomes.
Abstract

Keywords:
Antiphospholipid syndromeGestational hypertensionPreterm deliverySevere thrombocytopeniaUteroplacental insufficiency

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

196
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

500

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
636
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
738
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
3
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
483
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.4K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
3